Skip to main content

Monarch teaches at the International Summer School for Rare Disease Registries

Last week, I had the pleasure of teaching at the National Centre for Rare Diseases hosted by the Istituto Superiore di Sanità and Dr. Domenica Taruscio. This rare disease registry course is in its second year, and is focused on exposing the maintainers of rare disease registries various aspects of registry planning and management. I was very impressed with the specific way in which this course was run. The week started with a discussion of the different types of registries (aims, study design, data sources), management sustainability, and clinical outcomes analysis. This was followed by an innovative collaborative learning exercise in the afternoon, where the participants were broken up into three groups. The collaborative learning focused on positive interdependence, individual accountability, face-to-face interaction, group processing and exercise of small-group interpersonal skills - all skills needed to realize a quality registry resource in addition to simply being a quality pedagogical approach. Each group had a different rare disease scenario that they had to develop methods and strategies against using what they had learned in the morning session. On each of the following mornings for the rest of the week, they would learn new content such as reference standards and catalogues, coding of rare disease, omics links with biobanks, epidemiologic analyses and confounders, sample stratification, patient unique identifiers, quality assurance methods, data reporting and dissemination and informed consent. Each afternoon, they would then apply these themes to their ongoing scenarios such that the scenarios developed into robust full-fledged registry plans by the end of the week. The teamwork was amazing, as was the instructor engagement throughout the process.

We capped the week off with a Monarch presentation on "The application of the Human Phenotype Ontology" (HPO), where we discussed why rare disease phenotyping needs something more than standard clinical coding systems can provide. Many rare disease phenotypes are sprinkled throughout the literature and clinical notes in completely non-computable ways. The HPO was designed to address this problem and provide a structure on which to perform bioinformatics analyses. Phenotype comparisons can be between patients and known diseases, as shown in our recent paper where we used the HPO to help diagnose undiagnosed patients. Phenotype comparisons can also be across species as well, to aid candidate prioritization in tools such as Exomiser. We also discussed the Global Alliance for Genomics and Health Matchmaker exchange, and how the HPO was being used to identify cohorts in tools such as PhenomeCentral. Finally, we ended with a summary of tools being developed by Monarch to support quality assurance of phenotype data to aid clinicians during the course of their phenotyping. We believe that the efforts that Monarch is making to define an exchange standard for rare disease phenotyping will be of great value to the rare disease registry communities and are looking forward to working with them further on their data publication.

Popular posts from this blog

Finally, a medical terminology that patients, doctors, and machines can all understand.

By Nicole Vasilevsky, Mark Engelstad, Erin Foster, Julie McMurry, Chris Mungall, Peter Robinson, Sebastian Köhler, Melissa Haendel
For many patients with rare and undiagnosed diseases, getting an accurate diagnosis, or even finding the appropriate experts is a long and winding road. To accelerate and facilitate this process, we developed a medical vocabulary (“HPO”) which is comprised of 12,000 terms that doctors can use to codify the precise and distinct observations about patients and their conditions. The HPO is structured in a way that enables machines to intelligently compare a patient’s profile with what scientists worldwide have already uncovered about diseases and their genetic causes.
Until now, most of the HPO labels and synonyms were composed of clinical terms unfamiliar to patients. For example, a patient may know they are ‘color-blind’, but may not be familiar with the clinical term ‘Dyschromatopsia’. This is why we developed a layer of 5,000 corresponding terms that can b…

Why cross-species phenomics informatics is critical to the PMI

Genomics, electronic health records, participant-provided data, sensors, and mobile health technologies can all contribute to personalized medicine. However, we currently cannot achieve statistical correlations amongst these almost unlimited number of parameters that will be collected by the PMI and the depth of mechanistic understanding that will be required for treatment stratification and the development of novel, targeted therapies. The promise of personalized medicine requires deep knowledge of the relationships between genotype, phenotype, and environmental variables - but we simply don’t have enough data. For example, in the ExAC database there are 3,230 genes with near-complete depletion of predicted protein-truncating variants, where 72% of these genes having no currently established human disease phenotype. If we look across organisms, we see that of these 2311 genes with unknown causal phenotypes/diseases, 88% have an associated phenotype in an ortholog, with 56% having or…

Save the Date: Symposium on Linking Disease Model Phenotypes to Human Conditions

Monarch is co-hosting a NIH Symposium titled “Linking Disease Model Phenotypes to Human Conditions” on September 10-11, 2015 at the Fishers Lane Auditorium, NIH, Rockville, MD. 
The purpose of the meeting is to convene a colloquium on the current status of Phenomics and its role in closing the gap that exists between biomedical research and clinical medical practice. The wealth of whole organism, cellular, and molecular data generated in the research laboratory must be translated into clinically relevant knowledge that enables the physician to make the best possible treatment decisions. Phenomics is gaining momentum due to the availability of the complete genomes for many organisms as well as higher throughput methods to genetically modify model organism genomes and observe and record phenotypes. Disease models comprise some of the most important tools of biomedical research. The efficacy of the use of disease models is based upon the principles of evolutionary conservation between sp…